Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de John Tsai
Age : 53
Public asset : 6,990,345 USD
Country of residence : Unknown
Linked companies : Novartis AG

Biography of John Tsai 
Presently, John Tsai is Chief Medical Officer at Novartis AG. In his past career Dr. Tsai was Chief Medical Officer & SVP-Global Medical at Amgen, Inc. and Head-Clinical Development at Bristol Myers Squibb Co. He received a doctorate from the University of Louisville School of Medicine and an undergraduate degree from Washington University in St. Louis.


Current positions of John Tsai 
Holdings of John Tsai 
John Tsai : Personal Network 
Most Read News 
06/14ELON MUSK : Bitcoin tops $40,000 after Musk says Tesla could use it again
RE
06/08CHAMATH PALIHAPITIYA : Palihapitiya's $16 million bet on Clover worth $682 million on Reddit rally
RE
06/12JEFF BEZOS : Bid of $28 million wins a rocket trip to space with Bezos
RE
06/18PETER THIEL : Thiel-backed psychedelics startup Atai valued at $3.19 billion in Nasdaq debut
RE
06/11ELON MUSK : 'This car crushes' Musk says, as Tesla launches faster Model S 'Plaid'
RE
06/15JACK MA : Alibaba executive says founder Jack Ma 'lying low' - CNBC
RE
06/21WARREN BUFFETT : Buffett-backed Nubank in talks to hire U.S. IPO underwriters -sources
RE
06/10MARIA MARTINEZ : French Industrial Production Unexpectedly Declined in April
DJ
06/09MARIA MARTINEZ : German Exports Rose in April Despite Pandemic Restrictions
DJ
06/12JEFF BEZOS : Winning Ticket to Join Jeff Bezos in Space Costs Nearly $30 Million in Blue Origin Auction--3rd Update
DJ
More news


© 2021 People and Ownership :   
John Tsai : Connections 


Latest news about John Tsai 
06/11PRESS RELEASE  : Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria
DJ
06/07NOVARTIS'  : Iptacopan Trial in Rare Kidney Disease Meets Primary Endpoint
MT
06/06PRESS RELEASE  : Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)
DJ
06/03PRESS RELEASE  : Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera
DJ
06/03NOVARTIS'  : nuclear therapy helps men with prostate cancer live longer - data
RE
06/03PRESS RELEASE  : Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study
DJ
05/28PRESS RELEASE : Novartis reports one year results of Phase III MERLIN study evaluating Beovu(R) every four week dosing and provides update on Beovu clinical program
DJ
More news